The deal follows a joint-study for complex protein production, which saw “record” yields of non-antibody proteins produced in a human expression system.

In a joint statement, the firms said they “achieved a manufacturing yield of over three grams per ltr for a secreted, highly glycosylated non-antibody protein, using the challenging hAAT molecule which harbors 3N-glycosylation sites, through a combination of two highly innovative proprietary technologies.”

Kent Payne, VP and general manager of Catalent’s biologics business said: “We look forward to further drawing on this combination in the development of additional recombinant proteins and antibodies.”

This content is copyright protected

However, if you would like to share the information in this article, you may use the headline, summary and link below: